The Lacuna Project

lacuna (n.) a gap in a record where something should be

Independent research. Not affiliated with any government, agency, or company.

Exhibit 989

FDA Launches Crackdown on Deceptive Drug Advertising (press release)

Exhibit 989 · Agency press release

FDA Launches Crackdown on Deceptive Drug Advertising (press release)

Today, the FDA is sending thousands of letters warning pharmaceutical companies to remove misleading ads and issuing approximately 100 cease-and-desist letters to companies with deceptive ads.

Announces thousands of letters to pharmaceutical companies, about 100 cease-and-desist letters, and rulemaking to remove the “adequate provision” option created in 1997. States that FDA once sent more than a hundred warning letters a year and that those to pharmaceutical companies fell to one in 2023 and zero in 2024. Quotes the Commissioner: drug companies spend up to 25% of their budget on advertising. Letter counts are FDA’s own and were not independently checked.

Source
U.S. Food and Drug Administration
Date
9 September 2025
Quoted from
Para. 1
Grade
Primary record
Document
https://www.fda.gov/news-events/press-announcements/fda-launches-crackdown-deceptive-drug-advertising
Accessed
2026-11-10
Cited by
Findings citing this exhibit

Cited by

Finding INF-1.9
Primary record On 9 September 2025 the President directed HHS and FDA to act on direct-to-consumer drug advertising, and FDA announced thousands of warning letters, about 100 cease-and-desist letters and rulemaking to remove the "adequate provision" option. FDA's announcement states that warning letters to pharmaceutical companies fell to one in 2023 and zero in 2024.